Literature DB >> 23901057

Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population.

Roberto Lorbeer1, Sebastian E Baumeister, Marcus Dörr, Matthias Nauck, Anne Grotevendt, Henry Völzke, Ramachandran S Vasan, Henri Wallaschofski, Wolfgang Lieb.   

Abstract

AIMS: To assess the association of circulating concentrations of angiopoietin-2 (Ang-2) and its soluble receptor Tie-2 (sTie-2) with all-cause, cardiovascular, and cancer mortality in a population-based sample. METHODS AND
RESULTS: Angiopoietin-2 and sTie-2 were measured in 3220 participants (1665 women; mean age 54.4 years) in the Study of Health in Pomerania (SHIP). Multivariable adjusted hazard ratios (HRs) for mortality were estimated using Cox proportional hazard models. During a median follow-up of 6.2 years, 217 participants died. Ang-2 levels were positively associated with all-cause mortality [HR 1.29; 95% confidence interval (CI) 1.19-1.39 per 1 SD increment; P < 0.001] and cardiovascular mortality (HR 1.32; 95% CI 1.18-1.49; P < 0.001), but not with cancer mortality (HR 1.08; 95% CI 0.89-1.32; P = 0.416). Levels of sTie-2 were not significantly related to all-cause mortality (HR 1.12; 95% CI 0.98-1.27; P = 0.102). Adding Ang-2 to a prediction model for all-cause mortality with standard risk factors slightly improved discrimination (Δ Harrell's C, 0.008; P < 0.001) but not risk reclassification (continuous net reclassification improvement, -0.015; P = 0.571).
CONCLUSION: In our community-based sample, higher serum Ang-2 concentrations were associated with greater risk for all-cause and cardiovascular mortality, suggesting that subtle increases in Ang-2 levels might reflect processes such as vascular remodelling that are associated with higher mortality risk. Adding Ang-2 to a mortality prediction model only modestly improved discrimination.

Entities:  

Keywords:  Angiopoietin-2; Mortality; Population; Receptor Tie-2

Mesh:

Substances:

Year:  2013        PMID: 23901057     DOI: 10.1093/eurjhf/hft117

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  17 in total

1.  Stop the LVAD bleeding.

Authors:  Antigone Koliopoulou; Craig H Selzman
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Variants in angiopoietin-2 (ANGPT2) contribute to variation in nocturnal oxyhaemoglobin saturation level.

Authors:  Heming Wang; Brian E Cade; Han Chen; Kevin J Gleason; Richa Saxena; Tao Feng; Emma K Larkin; Ramachandran S Vasan; Honghuang Lin; Sanjay R Patel; Russell P Tracy; Yongmei Liu; Daniel J Gottlieb; Jennifer E Below; Craig L Hanis; Lauren E Petty; Shamil R Sunyaev; Alexis C Frazier-Wood; Jerome I Rotter; Wendy Post; Xihong Lin; Susan Redline; Xiaofeng Zhu
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 3.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

4.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

5.  Genome-wide association study for endothelial growth factors.

Authors:  Wolfgang Lieb; Ming-Huei Chen; Martin G Larson; Radwan Safa; Alexander Teumer; Sebastian E Baumeister; Honghuang Lin; Holly M Smith; Manja Koch; Roberto Lorbeer; Uwe Völker; Matthias Nauck; Henry Völzke; Henri Wallaschofski; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Circ Cardiovasc Genet       Date:  2014-12-31

6.  Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis.

Authors:  Chang Chu; Xin Chen; Ahmed A Hasan; Angelika Szakallova; Bernhard K Krämer; Martin Tepel; Berthold Hocher
Journal:  Nephrol Dial Transplant       Date:  2022-06-23       Impact factor: 7.186

7.  Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction.

Authors:  Seung-Jun Lee; Choong-Kun Lee; Seok Kang; Intae Park; Yoo Hyung Kim; Seo Ki Kim; Seon Pyo Hong; Hosung Bae; Yulong He; Yoshiaki Kubota; Gou Young Koh
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

8.  Complement promotes endothelial von Willebrand factor and angiopoietin-2 release in obstructive sleep apnea.

Authors:  Su Gao; Memet Emin; Theodosia Thoma; Kalliopi Pastellas; Francesco Castagna; Riddhi Shah; Alondra Jimenez; Neha Patel; Ying Wei; Sanja Jelic
Journal:  Sleep       Date:  2021-04-09       Impact factor: 5.849

9.  Associations of Angiopoietins With Heart Failure Incidence and Severity.

Authors:  Brandon S Peplinski; Brian A Houston; David A Bluemke; Steven M Kawut; Todd M Kolb; Richard A Kronmal; Joao A C Lima; David D Ralph; Samuel G Rayner; Zachary L Steinberg; Ryan J Tedford; Peter J Leary
Journal:  J Card Fail       Date:  2021-04-17       Impact factor: 6.592

10.  Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease.

Authors:  Yi-Chun Tsai; Chee-Siong Lee; Yi-Wen Chiu; Hung-Tien Kuo; Su-Chu Lee; Shang-Jyh Hwang; Mei-Chuan Kuo; Hung-Chun Chen
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.